The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612000381886
Ethics application status
Approved
Date submitted
28/03/2012
Date registered
3/04/2012
Date last updated
16/11/2015
Type of registration
Prospectively registered

Titles & IDs
Public title
High Concentration Oxygen in Fibrotic Lung Disease
Scientific title
Response of Patients with Fibrotic Lung Disease to Hyperoxia and Normoxia, as Measured by Carbon Dioxide Levels
Secondary ID [1] 280234 0
Nil
Universal Trial Number (UTN)
U1111-1129-5712
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Fibrotic Lung Disease 286183 0
Condition category
Condition code
Respiratory 286377 286377 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
50% oxygen administration for 30 minutes via a full-face continuous positive airway pressure mask without positive airway pressure. Followed by a 30 minute washout period.
Intervention code [1] 284568 0
Treatment: Other
Comparator / control treatment
21% oxygen administration for 30 minutes via a full-face continuous positive airway pressure mask without positive aiway pressure. Followed by a 30 minute washout period.
Control group
Placebo

Outcomes
Primary outcome [1] 286837 0
Transcutaneous carbon dioxide level, adjusted for baseline, as measured by a TOSCA monitor.
Timepoint [1] 286837 0
30 minutes.
Secondary outcome [1] 296783 0
Transcutaneous carbon dioxide level, adjusted for baseline, as measured by a TOSCA monitor.
Timepoint [1] 296783 0
10 and 20 minutes.
Secondary outcome [2] 296784 0
Minute ventilation, adjusted for baseline, calculated using a flow sensor attached to the expiratory port of the participant's mask.
Timepoint [2] 296784 0
10, 20 and 30 minutes.
Secondary outcome [3] 296785 0
Volume of dead space to tidal volume, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [3] 296785 0
10, 20 and 30 minutes.
Secondary outcome [4] 296786 0
Change in transcutaneous carbon dioxide greater than or equal to 4mmHg, as measured by a TOSCA monitor.
Timepoint [4] 296786 0
30 minutes.
Secondary outcome [5] 296787 0
Change in transcutaneous carbon dioxide greater than or equal to 10 mmHg, as measured by a TOSCA monitor.
Timepoint [5] 296787 0
30 minutes.
Secondary outcome [6] 296788 0
Tidal volume, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [6] 296788 0
10, 20 and 30 minutes.
Secondary outcome [7] 296789 0
Volume of dead space, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [7] 296789 0
10, 20 and 30 minutes.
Secondary outcome [8] 296790 0
Alveolar volume, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [8] 296790 0
10, 20 and 30 minutes.
Secondary outcome [9] 296791 0
Alveolar minute ventilation, adjusted for baseline, calculated using additional data from a flow sensor attached to the expiratory port of the participant's mask and volumetric capnography.
Timepoint [9] 296791 0
10, 20 and 30 minutes.
Secondary outcome [10] 296792 0
Oxygen saturations, adjusted for baseline, as recorded on the TOSCA via continuous electronic recording data download.
Timepoint [10] 296792 0
Continuously over the time course of the intervention and washout period.
Secondary outcome [11] 296793 0
Effect of baseline transcutaneous carbon dioxide, as recoded via the TOSCA, on outcome.
Timepoint [11] 296793 0
Value from baseline.
Secondary outcome [12] 296844 0
Heart rate, adjusted for baseline, as recorded on the TOSCA.
Timepoint [12] 296844 0
10, 20 and 30 minutes.
Secondary outcome [13] 296845 0
Respiratory rate, measured from capnography equipment.
Timepoint [13] 296845 0
10, 20 and 30 minutes.

Eligibility
Key inclusion criteria
Fibrotic lung disease by doctor's diagnosis and evidence of fibrosis on CT scanning
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Baseline transcutaneous carbon dioxide of greater than or equal to 60mmHg
Diagnosis of chronic obstructive pulmonary disease
FEV1:FVC less than or equal to 70%
Vital capacity greater than 80%
Over 20 pack year smoking history
Obesity (body mass index greater than or equal to 40)
Any other condition which, at the investigator's discretion, is believed may present a safety risk or impact the feasibility of the study or the study results

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Following explaination of the trial and consent, participants will be assessed for eligibility. If eilgible, participants will be randomised to the order of interventions (21% oxygen and 50% oxygen). This order will be available to an investigator who is not administering treatment, assessing outcomes or analysing data. Their role is to make available the gas bottles and bags (containing either 21% or 50% oxygen) in the randomised order. The labels on the bottles will be covered to maintain blinding of other investigators and the participant.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
By computer
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
Not Applicable
Type of endpoint(s)
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Suspended
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment outside Australia
Country [1] 4227 0
New Zealand
State/province [1] 4227 0

Funding & Sponsors
Funding source category [1] 284992 0
Government body
Name [1] 284992 0
Health Research Council of New Zealand
Address [1] 284992 0
Level 3 - ProCARE Building, Grafton Mews, at 110 Stanley Street, Auckland 1010
Country [1] 284992 0
New Zealand
Funding source category [2] 284993 0
Charities/Societies/Foundations
Name [2] 284993 0
Medical Research Institute of New Zealand
Address [2] 284993 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country [2] 284993 0
New Zealand
Primary sponsor type
Individual
Name
Janine Pilcher
Address
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country
New Zealand
Secondary sponsor category [1] 283858 0
Individual
Name [1] 283858 0
Richard Beasley
Address [1] 283858 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country [1] 283858 0
New Zealand
Other collaborator category [1] 260669 0
Individual
Name [1] 260669 0
Kyle Perrin
Address [1] 260669 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country [1] 260669 0
New Zealand
Other collaborator category [2] 260670 0
Individual
Name [2] 260670 0
Pip Shirtcliffe
Address [2] 260670 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country [2] 260670 0
New Zealand
Other collaborator category [3] 260671 0
Individual
Name [3] 260671 0
Mitesh Patel
Address [3] 260671 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country [3] 260671 0
New Zealand
Other collaborator category [4] 260672 0
Individual
Name [4] 260672 0
Mathew Williams
Address [4] 260672 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country [4] 260672 0
New Zealand
Other collaborator category [5] 260673 0
Individual
Name [5] 260673 0
Mark Weatherall
Address [5] 260673 0
Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country [5] 260673 0
New Zealand

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 287000 0
Health and Disability Ethics Committee: Central
Ethics committee address [1] 287000 0
1 The Terrace, Wellington 6011
Ethics committee country [1] 287000 0
New Zealand
Date submitted for ethics approval [1] 287000 0
21/12/2011
Approval date [1] 287000 0
23/03/2012
Ethics approval number [1] 287000 0
CEN/11/12/074

Summary
Brief summary
Oxygen therapy has been shown to increase carbon dioxide in the blood of patients with certain repiratory conditions. This study aims to find out if oxygen therapy increases carbon dioxide levels in patients with fibrotic lung disease and, if so, how.
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 33992 0
Dr Janine Pilcher
Address 33992 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country 33992 0
New Zealand
Phone 33992 0
+6448050241
Fax 33992 0
Email 33992 0
janine.pilcher@mrinz.ac.nz
Contact person for public queries
Name 17239 0
Dr Janine Pilcher
Address 17239 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country 17239 0
New Zealand
Phone 17239 0
+64 4 8050241
Fax 17239 0
+64 4 3895707
Email 17239 0
janine.pilcher@mrinz.ac.nz
Contact person for scientific queries
Name 8167 0
Dr Janine Pilcher
Address 8167 0
MRINZ, Wellington Regional Hospital, Riddiford Street, Newtown, Wellington 6021
Country 8167 0
New Zealand
Phone 8167 0
+64 4 8050241
Fax 8167 0
+64 4 3895707
Email 8167 0
janine.pilcher@mrinz.ac.nz

No information has been provided regarding IPD availability
Summary results
No Results